Goldman Sachs upgraded MoonLake Immunotherapeutics (MLTX) to Buy from Neutral with an $82 price target
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLTX:
- MoonLake Immunotherapeutics price target raised to $81 from $71 at BTIG
- MoonLake Immunotherapeutics initiates three new clinical trials
- Capricor, Gilead, Kymera, Praxis among Oppenheimer’s top biotech picks for 2025
- MoonLake Immunotherapeutics Announces Board Changes and Incentives
- MoonLake Immunotherapeutics management to meet with Oppenheimer